, Volume 35, Issue 9, pp 1409-1414
Date: 13 Jun 2010

Efficacy of celecoxib, meloxicam and paracetamol in elderly Kashin-Beck Disease (KBD) patients

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


The objective of this study was to compare the efficacy and tolerability of celecoxib, meloxicam and paracetamol in late Kashin-Beck disease. Adults (n = 168) with Kashin-Beck disease were randomised in clusters to receive six week courses of celecoxib 200 mg once daily, meloxicam 7.5 mg once daily or paracetamol 300 mg three times daily. Efficacy assessments included overall joint pain intensity and Western Ontario and McMaster Universities Osteoarthritis Index subscales; tolerability was evaluated by adverse event and physician reporting. Celecoxib and meloxicam were efficacious in relieving pain and improving stiffness, but unable to improve physical function after six weeks. Paracetamol was efficacious in relieving pain, but unable to improve morning stiffness and physical function after six weeks. Celecoxib and meloxicam provide predictable and sustained relief from pain and stiffness. Paracetamol can relieve the pain. None of the treatments improved impaired physical function in Kashin-Beck disease.

This study was partially supported by a grant from NSFC (Natural Science support project Item of China) 2007BA125B04 to Dr. Fuxing Pei ChiCTR-TCR-000000395.